Regulation of Renal Hemodynamics and Glomerular Filtration in Patients with Renovascular Hypertension During Converting Enzyme Inhibition with Captopril
Overview
Authors
Affiliations
Changes in regional hemodynamics and function of the kidney during inhibition of angiotensin converting enzyme were studied in 25 patients with renovascular hypertension. A variety of patterns were observed depending upon (1) the activity of the renin-angiotensin system and concomitant administration of diuretics, and (2) the presence of bilateral renal artery stenosis. Increase in blood flow, glomerular filtration rate and sodium excretion during angiotensin blockade, in some instances, indicated tonic renal vasoconstriction before therapy. Release of the kidney from these effects may explain, in part, the sustained effectiveness of converting enzyme inhibition in chronic congestive heart failure. When compared with blood pressure reduction due to nitroprusside administration, initial captopril therapy in patients with unilateral stenosis produced a selective decrease in glomerular filtration, despite well-preserved renal blood flow. These results confirm the importance of efferent arteriolar vasoconstriction due to angiotensin II in man. Experimental studies demonstrate that angiotensin may become critical to sustaining glomerular filtration rate in the presence of stenosis during vasodilation. In patients with bilateral stenosis, this effect produces a syndrome of functional renal insufficiency. Taken together, these data demonstrate an intrarenal action of angiotensin II in human renovascular hypertension and underscore the importance of evaluating the functional impact of changes in regional hemodynamics.
Jarraya F, Pruijm M, Wuerzner G, Burnier M Curr Hypertens Rep. 2013; 15(5):497-505.
PMID: 23897422 DOI: 10.1007/s11906-013-0376-x.
Gloviczki M, Glockner J, Gomez S, Romero J, Lerman L, McKusick M Invest Radiol. 2009; 44(9):566-71.
PMID: 19668000 PMC: 2990402. DOI: 10.1097/RLI.0b013e3181b4c1e8.
Atherosclerotic renovascular disease.
Tobe S, Burgess E, Lebel M Can J Cardiol. 2006; 22(7):623-8.
PMID: 16755319 PMC: 2560872. DOI: 10.1016/s0828-282x(06)70286-0.
ACE inhibitors and the kidney. A risk-benefit assessment.
Navis G, Faber H, de Zeeuw D, de Jong P Drug Saf. 1996; 15(3):200-11.
PMID: 8879974 DOI: 10.2165/00002018-199615030-00005.
Drug therapy of renovascular hypertension.
Rosenthal T Drugs. 1993; 45(6):895-909.
PMID: 7691497 DOI: 10.2165/00003495-199345060-00003.